Esomix D Capsule SR is a combination pharmaceutical formulation containing Domperidone 30 mg and Esomeprazole 40 mg, designed for the management of gastrointestinal disorders associated with acid reflux and delayed gastric emptying. Esomeprazole, a proton pump inhibitor, effectively suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, thereby providing symptomatic relief in conditions such as gastroesophageal reflux disease (GERD), erosive esophagitis, and Zollinger-Ellison syndrome. Domperidone, a peripheral dopamine D2 receptor antagonist, enhances gastrointestinal motility by accelerating gastric emptying and improving esophageal sphincter tone, which helps reduce symptoms like nausea, vomiting, and bloating. The sustained-release (SR) formulation ensures a prolonged therapeutic effect, optimizing patient compliance and maintaining stable plasma drug concentrations. Esomix D Capsule SR is indicated for patients requiring both acid suppression and prokinetic activity, particularly those with refractory GERD symptoms or functional dyspepsia. It should be administered under medical supervision, considering potential contraindications such as hypersensitivity to components, cardiac arrhythmias, or concomitant use of QT-prolonging agents. Common adverse effects may include headache, dry mouth, or gastrointestinal disturbances. Regular monitoring and adherence to prescribed dosage are essential to maximize therapeutic benefits and minimize risks.